NDA 020857 · Viiv Hlthcare
Combivir
Lamivudine, Zidovudine · Oral · Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Priority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: May 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Sep 26, 1997
Approved uses
2
Original approval plus efficacy supplements
Registered trials
737
226 Phase 3, 25 recruiting
FAERS reports
7,705
6,925 serious, 595 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEMATOLOGIC TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, and EXACERBATIONS OF HEPATITIS B Zidovudine, a component of COMBIVIR (lamivudine and zidovudine) tablets, has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV ‑ 1) disease [see Warnings and Precautions ( 5.1 )] . Prolonged use of zidovudine has been associated with symptomatic myopathy [see Warnings and Precautions ( 5.2 )] . Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, including lamivudine and zidovudine (components of COMBIVIR). Discontinue COMBIVIR if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur [see Warnings and Precautions ( 5.3 )] . Severe...
What it is approved for
From the label in effect Aug 22, 2023.
COMBIVIR, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. COMBIVIR, a combination of 2 nucleoside analogue reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. ( 1 )
Mechanism: COMBIVIR is an antiretroviral agent [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 2, 2009 Supplement 23 · Efficacy · priority review LetterLabel
- Sep 26, 1997 Original approval · Type 4 - New Combination · priority review
1 products under this application
- COMBIVIR · LAMIVUDINE 150MG; ZIDOVUDINE 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lamivudine" as an intervention, any sponsor and status, largest first.
University of WashingtonAcademic, hospital or other
NCT04666792 · 25,457 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2024
Drug: PrEP · For: HIV Infections; Contraception; STI
Sites: Kisumu, Kenya
- The Partners Scale-Up ProjectCompleted
University of WashingtonAcademic, hospital or other
NCT03052010 · 4,898 participants · Start Feb 6, 2017 · Primary completion Dec 15, 2020
Drug: PrEP; ART · For: HIV-1-infection
Sites: Kisumu, Kenya; Thika, Kenya
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited CountriesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01061151 · 3,747 participants · Start Mar 1, 2011 · Primary completion Sep 30, 2016
Drug: Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers and 6 more · For: HIV Infections
Sites: Pune, India; Blantyre, Malawi; Lilongwe, Malawi · 14 sites in all
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00074581 · 3,526 participants · Start Feb 2005 · Primary completion May 2015
Drug: Atazanavir; Didanosine and 8 more · For: HIV Infections
Sites: Boston, Massachusetts; Gaborone, Botswana; Nova Iguaçu, Brazil · 17 sites in all
- Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive WomenPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02181933 · 2,648 participants · Start Apr 1999 · Primary completion Jan 2001
Drug: Nevirapine; Zidovudine (ZDV) and 1 more · For: HIV Infections
- Breastfeeding, Antiretroviral, and Nutrition StudyPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT00164736 · 2,369 participants · Start Mar 2004 · Primary completion Jan 2010
Drug: Maternal zidovudine/lamivudine/lopinavir-ritonavir; Infant nevirapine · For: HIV Infections
Sites: Lilongwe, Malawi
- The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV DrugsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00002368 · 2,000 participants
Drug: Nevirapine; Lamivudine · For: HIV Infections
Sites: Montgomery, Alabama; Los Angeles, California; Palo Alto, California · 53 sites in all
- Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South AfricaActive, not recruiting
Professor Francois VenterAcademic, hospital or other
NCT07006246 · 1,900 participants (planned) · Start May 19, 2023 · Primary completion Nov 30, 2025
Drug: Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC) · For: HIV Infection
Sites: Johannesburg, South Africa
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug exposure during pregnancy1,147
- foetal exposure during pregnancy720
- pain601
- anxiety568
- emotional distress557
- anhedonia504
- anaemia453
- abortion spontaneous443
- maternal exposure during pregnancy381
- premature baby363
- chronic kidney disease327
- pyrexia285
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 503 |
| 2005 | 614 |
| 2006 | 564 |
| 2007 | 506 |
| 2008 | 479 |
| 2009 | 522 |
| 2010 | 664 |
| 2011 | 373 |
| 2012 | 401 |
| 2013 | 298 |
| 2014 | 332 |
| 2015 | 469 |
| 2016 | 245 |
| 2017 | 179 |
| 2018 | 266 |
| 2019 | 332 |
| 2020 | 339 |
| 2021 | 277 |
| 2022 | 184 |
| 2023 | 52 |
| 2024 | 49 |
| 2025 | 21 |
| 2026 | 18 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Combivir (Lamivudine/Zidovudine)
2024 spending
$42K
Beneficiaries
15
36 claims
Per beneficiary
$2,784
$15.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $361,109 |
| 2021 | $257,752 |
| 2022 | $231,984 |
| 2023 | $167,802 |
| 2024 | $41,767 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
Figueroa MI, Brites C, Cecchini D, et al. · Clin Infect Dis 2026 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL, Lu Y, Yoshida K, et al. · Lancet Infect Dis 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial.
Pereira F, Magagnoli J, Ambati M, et al. · Med 2025 · Randomized Controlled Trial, Research Support, N.I.H., Intramural
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, et al. · Lancet HIV 2020 · Clinical Trial, Phase III, Comparative Study
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, et al. · Lancet 2017 · Clinical Trial, Phase III, Comparative Study
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.